Multiple myeloma (MM) ranks second in malignant hematopoietic cancers, and the most
common anti-MM drugs easily generate resistance. CDK4/6 have been validated to play …

Aim: CDK4 and 6 are the key initiators in the transition from G1 to S phase in the cell cycle;
thus, inhibition of CDK4/6 is a promising strategy for cancer treatment. Materials & methods …

8503 Background: Deregulation of Cdk4 or Cdk6 is a hallmark in cancer. However,
conventional cancer therapy centers on empirical cytotoxic killing. Targeting the cell cycle …

Currently, multiple myeloma is not yet considered a curable disease. Despite the recent
advances in therapy, the average patient lifespan is still unsatisfactory. Recently, CDK9 …

Abstract Abstract 1877 Poster Board I-902 Background: PD 0332991 (PD) a potent orally
bioavailable small molecule, is the only known CDK4/CDK6-specific inhibitor. Through …

2527 Background: G1T28 is a highly potent and selective CDK4/6 inhibitor being developed
as an IV agent for targeted bone marrow chemoprotection and as an oral antineoplastic …

CDK4/6 pathway is an attractive chemotherapeutic target for antitumor drug discovery and
development. Herein, we reported the structure-based design and synthesis of a series of …

Abstract Cyclin-dependent kinase 6 (EC 2.7. 11.22) play significant roles in numerous
biological processes and triggers cell cycle events. CDK6 controlled the transcriptional …

Abstract Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, which block the transition from the
G1 to S phase of the cell cycle by interfering with Rb phosphorylation and E2F release, have …

The emergence of new drugs is a major feature of the treatment history of multiple myeloma
(MM), which also reflects the current incurability of MM. As a unique member of cyclin …